Filgen 300Mcg Injection 1Vial

How it works

It is a glycoprotein which regulates the production and release of functional neutrophils from the bone marrow. Recombinant methionyl human granulocyte-colony stimulating factor (r-Met-HU-G-CSF) i.e. filgrastimcauses marked increases in peripheral blood neutrophil counts within twenty four hours, with minor increases in monocytes. In some SCN (severe chronic neutropenia) patients filgrastim can also induce a minor increase in the number of circulating eosinophils and basophils relative to baseline; some of these patients may present with eosinophilia or basophilia already prior to treatment. Elevations of neutrophil counts are dose-dependent at recommended doses. Neutrophils produced in response to filgrastim show normal or enhanced function as demonstrated by tests of chemotactic and phagocytic function. Following termination of filgrastim therapy, circulating neutrophil counts decrease by 50% within 1 to 2 days, and to normal levels within 1 to 7 days.